TREATMENT.COM AI INC. ANNOUNCES CLOSING OF UPSIZED BROKERED LIFE OFFERING OF UNITS
Treatment.com AI Inc. (OTC: TREIF) has successfully closed its upsized brokered private placement, raising $3.3 million through the issuance of 6,600,000 units at $0.50 per unit. Each unit includes one common share and half a share purchase warrant, with warrants exercisable at $0.75 until March 13, 2027.
The company paid the underwriter, Ventum Capital Corp., a cash commission of $264,000 and issued 528,000 non-transferable broker warrants. The proceeds will be allocated to sales and administrative expenses, software research and development, and working capital purposes.
Treatment.com AI specializes in healthcare AI technology, having developed the Global Library of Medicine (GLM), an AI engine built with input from hundreds of healthcare professionals. The GLM platform provides clinical information, recommended tests, and billing codes to healthcare professionals, aiming to reduce administrative burden and improve patient care quality.
Treatment.com AI Inc. (OTC: TREIF) ha concluso con successo il suo collocamento privato brokerato ampliato, raccogliendo 3,3 milioni di dollari attraverso l'emissione di 6.600.000 unit脿 a 0,50 dollari per unit脿. Ogni unit脿 include una azione comune e mezza opzione di acquisto di azioni, con opzioni esercitabili a 0,75 dollari fino al 13 marzo 2027.
L'azienda ha pagato all'intermediario, Ventum Capital Corp., una commissione in contante di 264.000 dollari e ha emesso 528.000 warrant broker non trasferibili. I proventi saranno destinati a spese di vendita e amministrative, ricerca e sviluppo software e scopi di capitale circolante.
Treatment.com AI 猫 specializzata nella tecnologia AI per la salute, avendo sviluppato la Global Library of Medicine (GLM), un motore AI costruito con input da centinaia di professionisti sanitari. La piattaforma GLM fornisce informazioni cliniche, test raccomandati e codici di fatturazione ai professionisti della salute, con l'obiettivo di ridurre il carico amministrativo e migliorare la qualit脿 dell'assistenza ai pazienti.
Treatment.com AI Inc. (OTC: TREIF) ha cerrado con 茅xito su colocaci贸n privada brokerada ampliada, recaudando 3.3 millones de d贸lares a trav茅s de la emisi贸n de 6,600,000 unidades a 0.50 d贸lares por unidad. Cada unidad incluye una acci贸n com煤n y media opci贸n de compra de acciones, con opciones ejercitables a 0.75 d贸lares hasta el 13 de marzo de 2027.
La empresa pag贸 al suscriptor, Ventum Capital Corp., una comisi贸n en efectivo de 264,000 d贸lares y emiti贸 528,000 warrants de broker no transferibles. Los ingresos se destinar谩n a gastos de ventas y administrativos, investigaci贸n y desarrollo de software, y fines de capital de trabajo.
Treatment.com AI se especializa en tecnolog铆a de IA para la salud, habiendo desarrollado la Global Library of Medicine (GLM), un motor de IA construido con aportes de cientos de profesionales de la salud. La plataforma GLM proporciona informaci贸n cl铆nica, pruebas recomendadas y c贸digos de facturaci贸n a los profesionales de la salud, con el objetivo de reducir la carga administrativa y mejorar la calidad de la atenci贸n al paciente.
Treatment.com AI Inc. (OTC: TREIF)電� 靹标车鞝侅溂搿� 頇曤寑霅� 欷戧皽 靷 氚办爼鞚� 毵堦皭頃橁碃 330毵� 雼煬毳� 臁半嫭頃橃榾鞀惦媹雼�. 鞚措姅 雼渼雼� 0.50雼煬鞐� 6,600,000 雼渼毳� 氚滍枆頃� 瓴冹瀰雼堧嫟. 臧� 雼渼鞐愲姅 頃橂倶鞚� 氤错喌欤检檧 氚� 臧滌潣 欤检嫕 毵れ垬 甓岆Μ臧� 韽暔霅橃柎 鞛堨溂氅�, 甓岆Μ電� 2027雲� 3鞗� 13鞚缄箤歆� 0.75雼煬鞐� 頄夓偓頃� 靾� 鞛堨姷雼堧嫟.
須岇偓電� 鞚胳垬鞚胳澑 Ventum Capital Corp.鞐� 264,000雼煬鞚� 順勱笀 靾橃垬耄�毳� 歆�旮夗晿瓿� 528,000臧滌潣 鞏戨弰 攵堦皜電ロ暅 欷戧皽 甓岆Μ毳� 氚滍枆頄堨姷雼堧嫟. 靾橃澋旮堨潃 韺愲Г 氚� 甏�毽� 牍勳毄, 靻岉攧韸胳洦鞏� 鞐瓣惮 氚� 臧滊皽, 鞖挫榿 鞛愲掣 鞖╇弰搿� 靷毄霅� 瓴冹瀰雼堧嫟.
Treatment.com AI電� 鞚橂 AI 旮办垹鞚� 鞝勲鞙茧 頃橂┌, 靾橂氨 氇呾潣 鞚橂 鞝勲臧�鞚� 鞚橁铂鞚� 氚旐儠鞙茧 甑稌霅� Global Library of Medicine (GLM)鞚� 臧滊皽頄堨姷雼堧嫟. GLM 頂岆灚韽检潃 鞛勳儊 鞝曤炒, 於旍矞 瓴�靷� 氚� 觳惮 旖旊摐毳� 鞚橂 鞝勲臧�鞐愱矊 鞝滉车頃橃棳 頄夓爼 攵�雼挫潉 欷勳澊瓿� 頇橃瀽 旃橂 頀堨鞚� 臧滌劆頃橂姅 瓴冹潉 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
Treatment.com AI Inc. (OTC: TREIF) a r茅ussi 脿 clore son placement priv茅 broker茅 茅largi, levant 3,3 millions de dollars gr芒ce 脿 l'茅mission de 6 600 000 unit茅s 脿 0,50 dollar par unit茅. Chaque unit茅 comprend une action ordinaire et une demi-option d'achat d'actions, les options 茅tant exer莽ables 脿 0,75 dollar jusqu'au 13 mars 2027.
L'entreprise a vers茅 脿 l'underwriter, Ventum Capital Corp., une commission en esp猫ces de 264 000 dollars et a 茅mis 528 000 warrants de courtier non transf茅rables. Les produits seront affect茅s aux frais de vente et administratifs, 脿 la recherche et au d茅veloppement de logiciels, ainsi qu'脿 des fins de fonds de roulement.
Treatment.com AI se sp茅cialise dans la technologie d'IA pour la sant茅, ayant d茅velopp茅 la Global Library of Medicine (GLM), un moteur d'IA construit avec les contributions de centaines de professionnels de la sant茅. La plateforme GLM fournit des informations cliniques, des tests recommand茅s et des codes de facturation aux professionnels de la sant茅, visant 脿 r茅duire la charge administrative et 脿 am茅liorer la qualit茅 des soins aux patients.
Treatment.com AI Inc. (OTC: TREIF) hat erfolgreich seine erweiterte vermittelte Privatplatzierung abgeschlossen und 3,3 Millionen Dollar durch die Ausgabe von 6.600.000 Einheiten zu je 0,50 Dollar pro Einheit gesammelt. Jede Einheit umfasst eine Stammaktie und eine halbe Kaufoption, die bis zum 13. M盲rz 2027 zu 0,75 Dollar ausge眉bt werden kann.
Das Unternehmen zahlte dem Underwriter, Ventum Capital Corp., eine Bargeldprovision von 264.000 Dollar und gab 528.000 nicht 眉bertragbare Broker-Warrants aus. Die Erl枚se werden f眉r Vertriebs- und Verwaltungskosten, Softwareforschung und -entwicklung sowie Betriebskapital verwendet.
Treatment.com AI ist auf KI-Technologie im Gesundheitswesen spezialisiert und hat die Global Library of Medicine (GLM) entwickelt, eine KI-Engine, die mit Beitr盲gen von Hunderten von Gesundheitsfachleuten erstellt wurde. Die GLM-Plattform bietet klinische Informationen, empfohlene Tests und Abrechnungscodes f眉r Gesundheitsfachleute und zielt darauf ab, die administrative Belastung zu reduzieren und die Qualit盲t der Patientenversorgung zu verbessern.
- Successful capital raise of $3.3 million through private placement
- No hold period on units issued under Listed Issuer Financing Exemption
- Development of comprehensive AI healthcare platform (GLM) with 10,000+ expert medical reviews
- Share dilution through issuance of 6.6 million new units
- Additional potential dilution from 3.3 million warrants at $0.75
- Significant underwriting costs ($264,000 cash plus 528,000 broker warrants)
Vancouver, British Columbia, March 13, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the 鈥�Company鈥� or 鈥�Treatment鈥�) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that further to its news releases dated February 27, 2025 and March 3, 2025, it has closed its previously announced brokered private placement under the Listed Issuer Financing Exemption (the 鈥�Offering鈥�) with Ventum Capital Corp., (the 鈥淯苍诲别谤飞谤颈迟别谤鈥�) who acted as underwriter pursuant to an underwriting agreement dated March 13, 2025 (the 鈥淯nderwriting Agreement鈥�).
Dr. Essam Hamza, the Chief Executive Officer of Treatment, added: "We would like to thank the shareholders for the strong demand shown for this financing. I would also like to thank the teams at Ventum and Treatment for all the hard work they have put into getting this significant deal across the finish line. The added money will help us expedite our ambitious growth plans and we look forward to updating the market accordingly.鈥�
Pursuant to the Offering, the Company issued 6,600,000 units (the 鈥�Units鈥�) at the issue price of
The Offering was completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106听Prospectus Exemptions听(the 鈥�Listed Issuer Financing Exemption鈥�) and therefore the Units issued pursuant to the Offering are not subject to a hold period in accordance with applicable Canadian securities laws. There is an amended and restated offering document (the "Offering Document") related to the Offering that can be accessed under the Company's profile at and on the Company's website at . Prospective investors should read this Offering Document before making an investment decision.
The Company intends to use the proceeds from the Offering for sales and administrative expenses, software research and development and working capital purposes.
Pursuant to the Underwriting Agreement, the Company paid to the Underwriter a cash commission of
The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment鈥檚 GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment鈥檚 products and services: www.treatment.com or email:
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
For media inquiries, contact:
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statement
This news release contains forward-looking statements relating to the Offering and to future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, any statements regarding the use of proceeds of the Offering, and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment's expectations include risks detailed from time to time in the filings made by Treatment with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
听
FAQ
How much did Treatment.com AI (TREIF) raise in their March 2025 private placement?
What are the terms of the warrants issued in Treatment.com AI's March 2025 offering?
How will Treatment.com AI (TREIF) use the proceeds from the March 2025 offering?
What is Treatment.com AI's Global Library of Medicine (GLM) platform?
